TYLENOL ARTHRITIS

Compare TYLENOL ARTHRITIS  to:
Compare
Compare

Generic Name for TYLENOL ARTHRITIS

Acetaminophen 650mg; ext-rel caplets, geltabs.

Legal Classification:

OTC

Pharmacological Class for TYLENOL ARTHRITIS

Analgesic/antipyretic.

Manufacturer of TYLENOL ARTHRITIS

McNeil Consumer & Specialty Pharmaceuticals

Indications for TYLENOL ARTHRITIS

Minor arthritic pain.

Adult dose for TYLENOL ARTHRITIS

Swallow whole. >18yrs: 1.3g every 8 hrs; max 4g/day; usual max 10 days.

Children's dosing for TYLENOL ARTHRITIS

≤18yrs: not recommended.

Precautions for TYLENOL ARTHRITIS

Hepatic dysfunction. Pregnancy. Nursing mothers.

Interactions for TYLENOL ARTHRITIS

Hepatotoxicity risk increased by chronic, heavy alcohol use.

Adverse Reactions for TYLENOL ARTHRITIS

Hepatotoxicity (overdosage).

How is TYLENOL ARTHRITIS supplied?

Caplets—24, 50, 100, 150, 225
Geltabs—20, 40, 80

Related Disease:

Arthritis~NSAIDs

Related Resources

Xiaflex available for Dupuytren's contracture

March 08, 2010

BioSpecifics Technologies and Auxilium Pharmaceuticals announced the availability of Xiaflex (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord.

Xiaflex approved for Dupuytren's contracture

February 03, 2010

Auxilium Pharmaceuticals announced the approval of Xiaflex (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord.

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Phase 2 study of SBI-087 for treatment of rheumatoid arthritis (RA)

January 11, 2010

Trubion Pharmaceuticals announced the initiation of a Phase 2 trial of SBI-087 for the treatment of rheumatoid arthritis (RA).

Actemra approved for moderately to severely active rheumatoid arthritis

January 11, 2010

The FDA has approved Actemra (tocilizumab, from Roche) for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.